Khiron Life Sciences Corp.
KHRNH.V
TSX
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Net Income | -61.16% | 60.20% | 72.38% | -484.10% | 32.14% |
| Total Depreciation and Amortization | -16.71% | 8.71% | 291.51% | -55.60% | 2.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 100.20% | -188.59% | -88.18% | 1,809.59% | -252.23% |
| Change in Net Operating Assets | -297.81% | 183.29% | 80.99% | 118.58% | -157.52% |
| Cash from Operations | -146.69% | 29.21% | 46.01% | -6.41% | -116.36% |
| Capital Expenditure | -92.33% | -19.26% | 72.76% | -522.14% | 37.44% |
| Sale of Property, Plant, and Equipment | -- | -200.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -41.59% | -- | -- | 200.90% | -- |
| Cash from Investing | -79.99% | -52.17% | 79.11% | -587.40% | 28.04% |
| Total Debt Issued | 69,300.00% | -99.08% | 164.31% | -200.30% | -- |
| Total Debt Repaid | 166.54% | 16.17% | -147.27% | 663.10% | 114.41% |
| Issuance of Common Stock | -100.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.13% | -- | -- | 458.39% | -- |
| Cash from Financing | -76.58% | 1,945.50% | -140.98% | -95.75% | 1,952.65% |
| Foreign Exchange rate Adjustments | 357.69% | 9.90% | -45.73% | -171.75% | -33.29% |
| Miscellaneous Cash Flow Adjustments | -200.00% | -- | -- | -99.44% | -- |
| Net Change in Cash | -649.38% | 118.06% | 41.89% | -207.08% | 287.84% |
